DOC1021 is a multi-step process that harnesses the patient’s natural immune response, utilizing the manner in which the body mounts an anti-viral response to target and eliminate cancer cells. This treatment is fundamentally unique in three critical ways:
Use of Dendritic Cells Stimulated by Homologous Antigenic Loading (aka “Doubly-Loaded” Dendritic Cells): The autologous dendritic cell product is loaded ex vivo with autologous tumor mRNA and lysate containing MHC class I and II overlapping epitopes, mediating the activation of a highly-conserved, intrinsic signaling pathway that stimulates TH1 immunity.
Administration in the Vicinity of the Tumor Draining Lymph Nodes: By means of ultrasound sonography, the autologous dendritic cells are introduced near the deep cervical lymph nodes, the lymphatic chains that drain the CNS. This procedure permits responding T-cells to be specifically-targeted for extravasation at the CNS microvasculature.
Augmenting the Anti-Viral Response: The autologous dendritic cells are introduced to the patient on conjunction with systemic delivery of type I interferon (IFN-α2a) to prepare the cancer cells for immune attack via, among other things, upregulation of MHC class I molecules and activation of the immunoproteasome.
Currently, access to our Dendritic Cell Vaccine can be obtained through enrollment in one of our clinical studies for Glioblastoma Multiforme (NCT04552886) and Pancreatic Adenocarcinoma (NCT04157127). The objective of these clinical studies is to evaluate patient safety and efficacy.
For expanded access use to our investigational products, we encourage patients to contact us at email@example.com for an evaluation.
Diakonos Oncology will assess each request on a case-by-case scenario; however, we cannot guarantee that investigational products will be made available. In any requests for expanded access use, please consider the following the US Food and Drug Administration guidelines for Expanded Access Programs